Cingulate Overview

  • Status
  • Public

  • Employees
  • 14

Employees

  • Stock Symbol
  • CING

Stock Symbol

  • Share Price
  • $3.74
  • (As of Monday Closing)

Cingulate General Information

Description

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 1901 West 47th Place
  • Kansas City, KS 66205
  • United States
+1 (913)
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Biotechnology
Drug Delivery
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 1901 West 47th Place
  • Kansas City, KS 66205
  • United States
+1 (913)

Cingulate Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Cingulate Stock Performance

As of 16-Nov-2026, Cingulate’s stock price is $3.74. Its current market cap is $56M with 15M shares.

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.74 $4.33 $3.16 - $11.89 $56M 15M 124K -$2.67

Cingulate Financials Summary

As of 30-Sep-2026, Cingulate has a trailing 12-month revenue of null.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 49,870 27,786 6,030 8,786
Revenue 0 0 0 0
EBITDA (27,397) (20,548) (16,006) (22,176)
Net Income (29,187) (22,450) (16,560) (23,535)
Total Assets 28,151 15,073 14,864 3,491
Total Debt 4,535 8,787 5,099 3,510
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Cingulate Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Cingulate‘s full profile, request access.

Request a free trial

Cingulate Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug de
Pharmaceuticals
Kansas City, KS
14 As of 2025

Cranford, NJ
 

Cary, NC
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Cingulate Competitors (13)

One of Cingulate’s 13 competitors is Citius Pharma, a Formerly Angel backed company based in Cranford, NJ.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Citius Pharma Formerly Angel backed Cranford, NJ
Heron Therapeutics Formerly VC-backed Cary, NC
PDX Pharmaceuticals Venture Capital-Backed Portland, OR
Roivant Sciences Formerly PE-Backed New York, NY
BBS Nanotechnology Formerly VC-backed Debrecen, Hungary
You’re viewing 5 of 13 competitors. Get the full list »

Cingulate Patents

Cingulate Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
JP-2025091842-A Information processing device, method, program, and system Pending 08-Dec-2023
JP-2025091843-A Information processing device, method, program, and system Pending 08-Dec-2023
JP-2025091542-A Information processing apparatus, method, program, and system Pending 07-Dec-2023
JP-2025505781-A Trimodal precision timed release tablets Pending 16-Feb-2022
AU-2023222759-A1 Trimodal, precision-timed release tablet Pending 16-Feb-2022 A61K9/209
To view Cingulate’s complete patent history, request access »

Cingulate Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Cingulate Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Cingulate‘s full profile, request access.

Request a free trial

Cingulate ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view Cingulate’s complete esg history, request access »

Cingulate FAQs

  • Where is Cingulate headquartered?

    Cingulate is headquartered in Kansas City, KS.

  • What is the size of Cingulate?

    Cingulate has 14 total employees.

  • What industry is Cingulate in?

    Cingulate’s primary industry is Pharmaceuticals.

  • Is Cingulate a private or public company?

    Cingulate is a Public company.

  • What is Cingulate’s stock symbol?

    The ticker symbol for Cingulate is CING.

  • What is the current stock price of Cingulate?

    As of 16-Nov-2026 the stock price of Cingulate is $3.74.

  • What is the current market cap of Cingulate?

    The current market capitalization of Cingulate is $56M.

  • Who are Cingulate’s competitors?

    Citius Pharma, Heron Therapeutics, PDX Pharmaceuticals, Roivant Sciences, and BBS Nanotechnology are some of the 13 competitors of Cingulate.

  • What is Cingulate’s annual earnings per share (EPS)?

    Cingulate’s EPS for 12 months was -$2.67.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process